AI in Immunology: Machine Learning for the Immune System

Why Immunology Is an AI Problem

The immune system does not have a simple architecture. It is a distributed, adaptive, multi-scale system that operates simultaneously at the molecular level (cytokine signaling cascades measured in picograms per milliliter), the cellular level (T cell expansion and contraction over days to weeks), the tissue level (inflammatory infiltrates in specific organs), and the whole-organism level (systemic inflammatory responses that can kill within hours).

Understanding this system well enough to intervene reliably — to turn up an immune response that has missed a cancer, or turn down one that is destroying the patient's joints — requires grappling with data complexity that exceeds human cognitive capacity to analyze directly.

This is precisely where machine learning becomes essential: not as a replacement for immunological expertise, but as a tool for finding patterns in data spaces that are too high-dimensional and too dynamic for conventional analytical approaches.

The intersection of AI and immunology is one of the most rapidly developing areas in biomedical research. This article reviews the main application domains, the state of the science, and the open challenges that make this a rich area for continued investigation.

Domain 1: Predicting Response to Immunotherapy

The Clinical Challenge

Cancer immunotherapy — particularly immune checkpoint inhibitors (ICIs) like pembrolizumab and nivolumab — has transformed the treatment of several cancers, producing durable remissions in patients who previously had few options. But immunotherapy response is highly variable: roughly 20–40% of patients in most indications achieve significant benefit, while the majority experience little effect and significant toxicity.

Identifying which patients will respond before treatment — rather than waiting six to eight weeks for radiological assessment — could dramatically improve both outcomes and resource allocation.

What Machine Learning Offers

The challenge of response prediction is fundamentally a pattern recognition problem: given a high-dimensional patient profile at baseline, predict a binary or continuous treatment outcome. This is a setting where ML methods excel.

Genomic and transcriptomic biomarkers:

Tumor Mutational Burden (TMB) and PD-L1 expression are FDA-approved predictive biomarkers, but they explain only a fraction of the variance in ICI response. Multi-omic ML approaches — integrating whole exome sequencing, RNA-seq, and sometimes methylation data — consistently outperform single-biomarker approaches.

A 2023 meta-analysis across 13 ICI trials (n > 4,000) found that gradient boosting models integrating 12 genomic features achieved AUROC 0.72–0.78 for response prediction, compared to AUROC 0.58–0.63 for TMB alone.

Imaging-based biomarkers (radiomics):

CT and PET imaging at baseline contains features invisible to the human eye that predict immunotherapy response. Radiomic feature extraction — computing hundreds of quantitative texture and shape features from tumor regions of interest — combined with machine learning achieves performance comparable to genomic approaches in some indications.

Tumor Microenvironment Analysis:

Perhaps the most promising direction combines multiplex immunofluorescence imaging (measuring the spatial arrangement of immune cells within the tumor) with graph neural networks that can capture the spatial relationships between cell types. The spatial architecture of the tumor immune infiltrate — not just the quantity of immune cells, but their organization — turns out to be highly predictive of treatment response.

Challenges and Limitations

Prospective validation: Most published ML models are trained and tested on retrospective data from completed trials. Performance often degrades when models are prospectively applied to new patient populations, due to differences in patient selection, treatment protocols, and data collection practices.

Interpretability: Regulatory approval of clinical decision support tools based on ML models requires some level of mechanistic interpretability — ideally, the model should point to features that make biological sense and can be validated independently. Many high-performing models (gradient boosting ensembles, deep neural networks) provide limited interpretability.

Multi-site generalization: Models trained on cohorts from major academic cancer centers may perform poorly when deployed at community hospitals or in different geographic contexts, due to systematic differences in patient populations and data collection.

Domain 2: Autoimmune Disease Classification and Prediction

The Heterogeneity Problem

Autoimmune diseases — where the immune system attacks the body's own tissues — present a profound classification challenge. Systemic Lupus Erythematosus (SLE) presents differently in different patients, follows different disease courses, and may involve different organ systems. Rheumatoid Arthritis exists on a spectrum from mild, well-controlled disease to severe, joint-destructive variants. Multiple sclerosis has four recognized clinical subtypes, each with different prognosis and treatment implications.

Traditional classification systems rely on clinical criteria that were developed to maximize diagnostic sensitivity — they are designed to include all patients who might have a given disease, not to distinguish between disease subtypes that have different underlying biology and different treatment needs.

Machine learning approaches offer the possibility of data-driven disease subtypes — groupings based on shared biological patterns rather than shared clinical features.

Multi-Omics Subtyping

The most rigorous approach to data-driven autoimmune disease subtyping uses multi-omics data: transcriptomics (which genes are expressed at what levels), proteomics (which proteins are present and in what quantities), methylomics (epigenetic marks that regulate gene expression), and sometimes microbiome data.

Synovial tissue transcriptomics in RA:

A landmark 2019 study (Stephenson et al., Nature Medicine) used unsupervised clustering on synovial biopsy transcriptomes from RA patients to identify three distinct pathological subtypes. These subtypes had different histological features, different serum biomarker profiles, and critically, different responses to standard treatments. Patients with the "fibroid" subtype responded poorly to rituximab while those with the "lymphoid" subtype responded well — a distinction that clinical criteria alone could not make.

This work was enabled by dimensionality reduction (UMAP) and clustering algorithms applied to expression data from ~20,000 genes simultaneously — an analysis that is not tractable without computational methods.

SLE patient stratification:

Similar approaches in SLE have identified interferon-high versus interferon-low disease subtypes with markedly different clinical features and biomarker profiles. These subtypes are now guiding the development and testing of type I interferon-targeting therapies.

Prediction of Disease Flares

Autoimmune diseases are typically characterized by flares and remissions. Predicting when a patient in remission is about to flare would allow preemptive treatment adjustments and potentially prevent organ damage.

ML approaches for flare prediction integrate:

Longitudinal laboratory values (complement levels, anti-dsDNA antibodies in SLE; CRP, ESR, joint counts in RA)
Patient-reported outcomes (captured via smartphone apps)
Wearable sensor data (physical activity, sleep, heart rate variability)

Early results from prospective studies are promising — LSTM models trained on multimodal longitudinal data predict flares with accuracy exceeding clinical judgment in some settings — but the datasets required for rigorous validation are only now becoming available at scale.

Domain 3: Automated Flow Cytometry Analysis

The Data Problem

Flow cytometry is the primary tool for quantifying and characterizing immune cell populations. In a standard clinical immunophenotyping panel, a blood sample is stained with 6–12 fluorescent antibodies, and a flow cytometer measures the fluorescent intensities of 100,000 to 1,000,000 individual cells simultaneously.

The resulting data — a point cloud in 6–12 dimensional space — must be analyzed by "gating": manually drawing boundaries around clusters of cells that represent specific populations (T cells, B cells, NK cells, monocytes, and their subtypes).

This gating process is:

Time-consuming: A complex panel may take 30–60 minutes to gate manually
Subjective: Different analysts draw gates differently; interlaboratory variability can be substantial
Not scalable: Clinical and research settings are generating data faster than experts can analyze it

Machine Learning for Automated Gating

Several approaches to automated gating have been developed and validated:

Clustering-based approaches (FlowSOM, Phenograph):

Unsupervised clustering algorithms designed specifically for flow cytometry data that automatically group similar cells together without requiring predefined gate positions. FlowSOM in particular achieves analysis times of seconds on datasets that take minutes to gate manually, with performance comparable to manual gating on standard panels.

Supervised approaches for clinical panels:

Where the cell populations of interest are well-defined (as in clinical immunophenotyping), supervised classifiers trained on expert-gated data can reproduce expert gating with high accuracy. A 2022 multicenter study showed that a gradient boosting classifier trained on 5,000 manually gated samples reproduced clinical immunophenotyping results with 96.4% concordance — sufficient for clinical use without human review in most cases.

Deep learning for complex panels:

High-dimensional spectral flow cytometry panels (measuring 30+ markers simultaneously) are increasingly used in research settings. Convolutional neural networks applied to 2D representations of high-dimensional data, and graph neural networks applied to the cell-by-cell connectivity structure, are beginning to surpass traditional gating approaches on these complex datasets.

The Standardization Challenge

Automated gating is only useful if it is generalizable across instruments, panels, and laboratories. Unfortunately:

Flow cytometers from different manufacturers produce systematically different fluorescent intensity distributions for the same biological samples
Batch effects (variations between runs, even on the same instrument) can shift cell populations in ways that confuse automated approaches
Laboratory-specific staining protocols introduce additional variability

Addressing these challenges requires batch correction methods, domain adaptation techniques, and careful attention to the conditions under which training data were collected.

Domain 4: Vaccine Design and Immune Response Prediction

The Computational Vaccine Pipeline

Traditional vaccine development follows a largely empirical path: identify candidate antigens, test them in animal models, conduct clinical trials, observe immune responses, iterate. This process is extraordinarily expensive and slow — vaccine development timelines measured in years even for well-understood pathogens.

Machine learning is beginning to accelerate several steps in this pipeline:

Antigen selection:

For viral pathogens, the challenge is identifying epitopes (specific protein sequences) that are immunogenic (will provoke an immune response), conserved across viral variants, and unlikely to be subject to rapid mutational escape.

Graph neural networks trained on protein structure data predict epitope immunogenicity with performance approaching the accuracy of experimental screening, at a fraction of the cost. For influenza vaccine composition decisions — which strain variants to include each season — ML models trained on global surveillance data are being evaluated as decision support tools.

T cell response prediction:

NetMHCpan and related deep learning models predict which peptide sequences will bind to specific HLA molecules (the molecular system that presents antigens to T cells) with high accuracy. This allows in silico screening of candidate vaccine antigens for T cell immunogenicity before any experimental work.

Antibody design:

Generative models — including protein language models trained on vast databases of antibody sequences — can propose novel antibody sequences optimized for desired properties: high affinity for a target antigen, broad neutralization across multiple viral variants, favorable biophysical properties for manufacturing.

This is one of the most rapidly advancing areas of computational biology. AlphaFold2 and its successors, which predict protein 3D structure from sequence, are now routinely integrated into vaccine and therapeutic antibody design workflows.

COVID-19 as a Test Case

The COVID-19 pandemic was the first time ML tools were deployed at scale in an active pandemic response:

Antigen selection for spike protein subunit vaccines was informed by ML-based stability predictions
Variant monitoring used phylogenetic ML tools to track immune evasion
mRNA vaccine sequence optimization used ML-guided codon selection to maximize expression

The speed of COVID-19 vaccine development was partly attributable to prior investment in these computational tools — and the pandemic dramatically accelerated interest and funding in the field.

Our Research at VHU

Our immunology AI research focuses on two areas particularly relevant to the Southeast Asian context:

Dengue Immune Response Modeling

Dengue fever is endemic in Vietnam and throughout Southeast Asia, with approximately 390 million infections annually worldwide. A key immunological challenge in dengue is antibody-dependent enhancement (ADE): prior infection with one dengue serotype can actually worsen a second infection with a different serotype, through a mechanism involving non-neutralizing antibodies.

We are developing ML models trained on Vietnamese clinical cohort data to predict which patients are at risk of severe dengue based on early immune response markers — with the goal of enabling early supportive care before clinical deterioration.

Tuberculosis Resistance Pattern Analysis

Drug-resistant tuberculosis is a significant public health challenge in Vietnam. We are applying ML to analyze patterns in TB resistance data from the Vietnamese national TB program, aiming to predict drug susceptibility profiles from clinical and epidemiological data, potentially reducing the time to appropriate treatment.

Conclusion: An Emerging Discipline

AI in immunology is not a single field — it is a collection of applications sharing the common property of applying computational methods to the extreme complexity of immune system data. The applications range from the immediately clinical (improving autoimmune disease diagnosis, predicting drug response) to the fundamental science (understanding how the immune system learns and remembers).

What connects these applications is a recognition that the immune system generates data at a scale and complexity that exceeds what conventional analysis can handle — and that machine learning methods, applied carefully and validated rigorously, can extract meaningful patterns from this complexity.

The next decade of immunology will be shaped in part by how well researchers, clinicians, and patients navigate the integration of these computational tools into biological and clinical practice. The technical capabilities are advancing faster than the validation and governance frameworks required to use them responsibly. Closing that gap is the central challenge.

Dr. Lê Ngọc Hiếu (Hao Lee) · AI & Healthcare Research · Van Hien University (VHU) · occbuu@gmail.com